Literature DB >> 26397244

Shifting Autologous Breast Reconstruction into an Ambulatory Setting: Patient-Reported Quality of Recovery.

Kristen Davidge1, Kathleen A Armstrong, Mitchell Brown, Pamela Morgan, Mary Li, Lisa Cunningham, John L Semple.   

Abstract

BACKGROUND: As bundled payment models gain popularity, it is imperative that providers use patient outcomes and patient experience to define evidence-based pathways of care. The purpose of this study was to evaluate the quality of recovery experienced by women undergoing early discharge (<24 hours) after autologous breast reconstruction with a pedicled flap and determine predictors of postoperative quality of recovery.
METHODS: A prospective cohort study was performed on all women undergoing autologous breast reconstruction at Women's College Hospital between September of 2011 and July of 2013 that met study inclusion criteria. The patient-reported Quality of Recovery-27 questionnaire was used to measure quality of recovery on postoperative days 1, 2, 4, and 7. Preoperative and postoperative day 7 Quality of Recovery-27 questionnaire scores were compared. A multivariable random effect model for longitudinal data was used to evaluate any relationship between postoperative Quality of Recovery-27 questionnaire scores and American Society of Anesthesiologists classification, body mass index, and pain. Secondary analyses of delayed discharge (>24 hours) and complications were also undertaken.
RESULTS: Forty women, aged 28 to 69 years, were included in this study. There was no statistically significant difference between the preoperative and postoperative day 7 Quality of Recovery-27 questionnaire scores, suggesting that our patients recovery to their preoperative state by postoperative day 7. Poorer total Quality of Recovery-27 questionnaire scores were associated with higher American Society of Anesthesiologists classification, low and high body mass indexes (U-shaped relationship), and higher pain scores.
CONCLUSION: Patients undergoing an ambulatory pathway of care for autologous breast reconstruction demonstrate acceptable quality of recovery. CLINICAL QUESTION/LEVEL OF EVIDENCE: Risk, III.

Entities:  

Mesh:

Year:  2015        PMID: 26397244     DOI: 10.1097/PRS.0000000000001575

Source DB:  PubMed          Journal:  Plast Reconstr Surg        ISSN: 0032-1052            Impact factor:   4.730


  5 in total

Review 1.  Enhanced Recovery Pathways for Flap-Based Reconstruction: Systematic Review and Meta-Analysis.

Authors:  Yan Yu Tan; Frank Liaw; Robert Warner; Simon Myers; Ali Ghanem
Journal:  Aesthetic Plast Surg       Date:  2021-04-05       Impact factor: 2.326

2.  Effect of Home Monitoring via Mobile App on the Number of In-Person Visits Following Ambulatory Surgery: A Randomized Clinical Trial.

Authors:  Kathleen A Armstrong; Peter C Coyte; Mitchell Brown; Brett Beber; John L Semple
Journal:  JAMA Surg       Date:  2017-07-01       Impact factor: 14.766

3.  Transversus Abdominis Plane Blocks with Single-Dose Liposomal Bupivacaine in Conjunction with a Nonnarcotic Pain Regimen Help Reduce Length of Stay following Abdominally Based Microsurgical Breast Reconstruction.

Authors:  Eric M Jablonka; Andreas M Lamelas; Julie N Kim; Bianca Molina; Nathan Molina; Michelle Okwali; William Samson; Mark R Sultan; Joseph H Dayan; Mark L Smith
Journal:  Plast Reconstr Surg       Date:  2017-08       Impact factor: 5.169

4.  Analysis of Rinsing Fluid during Negative Pressure Wound Therapy with Instillation: A Potential Monitoring Tool in Acute and Chronic Wound Treatment. A Pilot Study.

Authors:  Christian D Taeger; Stefan Wallner; Teresa Martini; Daniel Schiltz; Andreas Kehrer; Lukas Prantl; Niklas Biermann
Journal:  Cells       Date:  2021-03-26       Impact factor: 6.600

5.  Immediate Prosthesis Breast Reconstruction: A Comparison Between Ambulatory Surgery Versus Traditional Hospitalization Based on the Propensity Score Matching Method.

Authors:  Xiao Chen; Aoxiang Chen; Chaoqi Liu; Bin Zhang
Journal:  Aesthetic Plast Surg       Date:  2022-10-06       Impact factor: 2.708

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.